It would be interesting to know his reasons for getting himself vaccinated with an mRNA vaccine when the ARR is so low, especially if he lives in an area where the background infection rate is low. Did he say? I guess it must have been more about 'for the greater good' than his own protection?5. I asked a noted immunologist, who is a critic of Big Pharma, his opinion about the mRNA vaccines. He told me that he and all his family members and relatives have been vaccinated with mRNA vaccine. Even though the 95% or so protection claimed by the Pfizer and Moderna are based on relative reduced risk and the absolute reduced risk is about 1%, in a pandemic he said that means a lot of lives saved.
We've got the second highest vaccination rate in the world, yet over here (in the UK) the new India variant is surging in many parts of the country (albeit ICU cases, so far, don't seem to be all that high). There's also a new seemingly 'home grown' variant that's suddenly appeared in the English county of Yorkshire. How infectious and 'deadly' the Yorkshire variant is is still being assessed. Maybe our Government's policy of making people wait up to 12 weeks for their second jabs has something to do with this.4. Here in California the only real change since last year has been mass vaccination, Before then, anytime they opened the economy we ended up with a surge of cases. In two weeks they expect complete reopening of all business to 100% capacity.
I too wonder if any of the concerns raised in that article have been observed so far. I've not seen much mention of ADE and not in relation to any of the new variants in my country. I hate thinking like this, but I wonder whether the 'powers that be' in the UK might not let on about ADE if it were to be happening now or in the future...They didn't, for instance, mention anything at all about rare blood clots with low platelets suffered by some of those receiving the AstraZeneca vaccine, not until Norway and the EU alerted the world to it, yet in the UK we'd already had as many cases as Germany and Norway.3. With autoimmune disease you need to be very careful. Here’s an article from the Proceedings of The National Academy of Sciences titled, “Avoiding pitfalls in the pursuit of a COVID-19 vaccine” published 3/30/2020. I wonder if any of the concerns raised in the article have been observed so far.
https://www.pnas.org/content/117/15/8218 (News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine)
With regard to the covid vaccine trials not including people with autoimmune diseases, I've just seen (on this website https://www.autoimmuneinstitute.org/covid-news-and-autoimmune-disease/ (Covid-19 News As It Relates to Autoimmune Disease | Global Autoimmune Institute)) that the following trial is going to take place. I might wait for the results of the trial to make up my mind about having the jabs, but goodness knows how long that might be!
"THE COVID-19 VACCINE AND IMMUNE DISORDERS
April 27, 2021
The NIH will be conducting a clinical trial testing COVID-19 vaccine responses in people with immune deficiencies. These will include primary and secondary immune system disorders. In addition to learning how this population responds to the COVID-19 vaccine, this study aims to fill the gap regarding the clinical presentation of COVID-19 in those with immune deficiencies, “especially those who have inborn conditions involving deficits or dysregulations in antibody or cell-based immune responses to infections.”
Because those with immune disorders were excluded from the COVID-19 vaccine clinical trials prior to emergency authorization, this study will “characterize the features and adequacy of immune responses to COVID-19 vaccination in people with a range of immune deficiencies and dysregulation syndromes.” The study will include 500 participants, 400 of which have primary or secondary immune system disorders and are 16 years of age or older. If participants get vaccinated during the study, blood samples will be taken before and after vaccination and studied for “short-term immunological effects of immunization.”
Participants may voluntarily provide blood samples at different intervals following their last dose of the vaccine. Researchers will then assess the T-cell response and vaccine-induced antibody production in those with immune disorders compared to those without immune system disorders.
For more information regarding the study and enrollment, visit clinicaltrials.gov and use the search code NCT04852276."
Last edited: